Latest News and Press Releases

Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) ...

Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly...

Company announcement – No. 40 / 2022 Zealand Pharma grants warrants to employees in Denmark Copenhagen, DK and Boston, MA, September 13, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no....

Company announcement – No. 39 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, DK and Boston, MA, September 8, 2022 – Zealand Pharma...

Press release – No. 4/ 2022 Zealand Pharma to Participate in Morgan Stanley 20th Annual Global Healthcare Conference Copenhagen, DK and Boston, MA, September 7, 2022 – Zealand Pharma A/S (Nasdaq...

Company announcement – No. 38 / 2022 Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million to Zealand in addition to...

Company announcement – No. 37 / 2022 Total number of shares and voting rights in Zealand Pharma at August 31, 2022 Copenhagen, DK and Boston, MA, August 31, 2022 – Zealand Pharma A/S (“Zealand”)...

COMPANY ANNOUNCEMENT – NO. 36 / 2022 Copenhagen, DK and Boston, MA, August 24, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the...

Company announcement – No. 35 / 2022 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, DK and Boston, MA, August 18, 2022 – Zealand Pharma A/S...

Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half of 2022 Copenhagen, DK and Boston, MA, U.S. August 11, 2022 – Zealand...